Raltitrexed

Raltitrexed Basic information
Product Name:Raltitrexed
Synonyms:RALTITREXED;(s)-2-[(1-{5-[methyl-(2-methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-amino]-thiophen-2-yl}-methanoyl)-amino]-pentanedioic acid;ICI-D-1694;N-[[5-[[(1,4-Dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-L-glutamic Acid;Tomudex;ZD-1694;L-Glutamic acid, N-[[5-[[(3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]-;(S)-2-(5-(METHYL((2-METHYL-4-OXO-3,4-DIHYDROQUINAZOLIN-6-YL)METHYL)AMINO)THIOPHENE-2-CARBOXAMIDO)PENTANEDIOIC ACID
CAS:112887-68-0
MF:C21H22N4O6S
MW:458.49
EINECS:652-997-2
Product Categories:Active Pharmaceutical Ingredients;Raltitrexed;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors;112887-68-0
Mol File:112887-68-0.mol
Raltitrexed Structure
Raltitrexed Chemical Properties
Melting point 176-1800C
density 1.49±0.1 g/cm3(Predicted)
storage temp. 2-8°C
solubility H2O: ≥10mg/mL
pka3.50±0.10(Predicted)
form solid
color off-white to light yellow
InChIKeyIVTVGDXNLFLDRM-HNNXBMFYSA-N
CAS DataBase Reference112887-68-0(CAS DataBase Reference)
Safety Information
Hazard Codes Xi,T
Risk Statements 36/38-25-61
Safety Statements 26-37/39-45-53
RIDADR UN 2811 6.1 / PGIII
WGK Germany 2
HS Code 2934.99.4700
MSDS Information
Raltitrexed Usage And Synthesis
DescriptionTomudex was launched in Ireland, France, Luxembourg and the UK for advanced colorectal cancer and it was prepared in a convergent manner (6 steps) from diethyl L-glutamate and 6-bromomethyi-2-methyl-quinazolin4(3H)-one. Tomudex is a highly selective inhibitor of thymidylate synthase (TS), the key enzyme in the biochemical conversion of dUMP to dTMP. It enters the cell via the reduced folatefmethotrexate cell membrane carrier and is converted to the polyglutamate species by folylpolyglutamate synthase within 4h where it then binds to the folate substrate site of TS. Clinically, it had a 29% response rate in patients with advanced colorectal cancer. It is water soluble, can be administered as a single dose every three weeks and had no hepto- or nephrotoxicity.
Chemical PropertiesYellow Crystalline Powder
OriginatorZeneca (UK)
UsesFolate-based inhibitor of thymidylate synthase; rapidly and extensively metabolized to its more potent polyglutamate derivatives. Antineoplastic
DefinitionChEBI: ICI D1694 is a N-acyl-amino acid.
Brand nameTomudex (Zeneca).
Biochem/physiol ActionsRaltitrexed is a folate-based inhibitor of thymidylate synthase (TS) that is rapidly and extensively metabolized to its more potent polyglutamate derivatives. By inhibiting the formation of precursor pyrimidine nucleotides, raltitrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.
Clinical UseTreatment of colorectal cancer when fluorouracil and folinic acid cannot be used
Drug interactionsPotentially hazardous interactions with other drugs
Antipsychotics: avoid with clozapine, increased risk of agranulocytosis.
Folic and folinic acid: impairs cytotoxic action - avoid.

MetabolismRaltitrexed is actively transported into cells and metabolised to active polyglutamate forms.
The remainder of a dose is not metabolised and is excreted unchanged, about 50% of a dose appearing in the urine, and about 15% in the faeces.
Raltitrexed Preparation Products And Raw materials
Raw materialsN-Bromosuccinimide-->DIETHYL GLUTAMATE
Methotrexate BI 2536 Pemetrexed Disodium Bosutinib 5-Fluorouracil Y27632 (hydrochloride) Milrinone 5-nitro-2-thiophenic acid (intermediate of raltitrexed) 5-(DIMETHYLAMINO)THIOPHENE-2-CARBALDEHYDE 2-[(2-thienylmethyl)amino]-1-butanol Raltitrexed 3-DIMETHYLAMINOMETHYL-BENZYLAMINE (THIOPHENE-2-CARBONYL)-AMINO]-ACETIC ACID 1400W 6-(bromomethyl)-3,4-dihydro-2-methyl-4-oxoquinazoline (intermediate of raltitrexed) 4-HYDROXY-6-METHYLQUINAZOLINE Quinazoline 2-AMINO-5-METHYLBENZAMIDE

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.